Semaglutide Half-Life: How Long It Stays in Your System
How long Semaglutide stays in the body, how that shapes dosing frequency, and what is known about drug testing.
- Half-life
- approximately 1 week
- subcutaneous, in people · FDA label (Ozempic)
- Dosing interval
- Varies by study
- as used in studies
- WADA
- Not listed
- 2026 Prohibited List
- Detection window
- Not found
- None reported as of 2 Oct 2026
Semaglutide half-life
A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray) and the species it was measured in, so we report each value with its route and source.
| Route | Half-life | Measured in | Source |
|---|---|---|---|
| subcutaneous | approximately 1 week | People | FDA label (Ozempic) |
| subcutaneous and oral | approximately 1 week | People | FDA label (Wegovy) |
| subcutaneous | approximately 1 week | People | The New England journal of medicine 2016, PMID 27633186 |
| As labelled | approximately 1 week (subcutaneous) | People | FDA label (Ozempic) |
| As labelled | approximately 1 week (injectable and oral) | People | FDA label (Wegovy) |
| As labelled | approximately one week (oral) | People | FDA label (Rybelsus, Ozempic tablets) |
Other pharmacokinetic findings (these are not half-life values):
| Route | Half-life | Measured in | Source |
|---|---|---|---|
| oral | approximately one week | People | FDA label (Rybelsus, Ozempic tablets) |
What half-life means
Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.
- A long half-life lets a drug be dosed less often, for example once a week.
- A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
- Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.
What it means for dosing frequency
Dosing intervals used in published studies of Semaglutide:
- once-daily, oral (Human RCT; Lancet 2026, PMID 41865758)
- once-weekly, subcutaneous (Human RCT; The New England journal of medicine 2025, PMID 40305708)
- once daily, oral (Human RCT; The New England journal of medicine 2025, PMID 40934115)
- once-weekly, subcutaneous (Human RCT; The lancet. Diabetes & endocrinology 2025, PMID 40961952)
Changing the interval changes how much drug builds up between doses, so it is not a free choice.
Drug tests and sport
Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Anti-doping labs use tests built for specific substances. Whether a given test detects Semaglutide, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026).
What the three semaglutide labels say
The Ozempic label puts the elimination half-life at about 1 week and says semaglutide stays in the circulation for about 5 weeks after the last dose.[2]
The Wegovy label gives the same half-life but a longer tail of 5 to 7 weeks, stated for the 2.4 mg and 7.2 mg injections and the 25 mg tablet.[3]
The Rybelsus label gives a half-life of about a week and an absolute clearance of about 0.04 L/hour in people with type 2 diabetes.[5]
Five half-lives in weeks
With a 1-week half-life, 5 half-lives is 5 weeks, which leaves about 3% of the drug. This is consistent with the Ozempic label's 5-week figure.
Calculated from half life 1 weeks; after 1 half-lives (1 weeks) 50.0% of the original amount; after 3 half-lives (3 weeks) 12.5% of the original amount; after 5 half-lives (5 weeks) 3.1% of the original amount. Formula: remaining fraction = 0.5^(weeks since last dose / 1 week)
Anti-doping status
WADA's S0 class applies only to substances with no current approval by a government health authority. Semaglutide has FDA approvals (the labels above), so S0 does not describe it.[1]
Common questions
How long does Semaglutide stay in your system?
Its reported half-life is approximately 1 week (subcutaneous); approximately 1 week (subcutaneous and oral). Most of a dose is gone after about four to five half-lives.
What is the half-life of semaglutide?
Labels for the injection and the tablet both give approximately 1 week.[2]
Is Semaglutide on the WADA prohibited list?
No, it is not listed. GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
What is the half-life of Ozempic?
Ozempic's label says about 1 week, with the drug present in the circulation for about 5 weeks after the last dose.[2]
What is the half-life of Wegovy?
Wegovy's label also says about 1 week, but quotes a 5 to 7 week presence after the last injectable or oral dose.[3]
Does Ozempic show up on a drug test?
The sources used here cover only WADA's list, not workplace drug panels. WADA's S0 class is limited to substances with no current approval, and Ozempic is approved.[1]
More on Semaglutide
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 3These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGFDA label (Wegovy), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 4Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2016PMID 27633186Accessed 2 Oct 2026
- 5These highlights do not include all the information needed to use RYBELSUS ® and OZEMPIC ® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets. RYBELSUS (FDA label (Rybelsus, Ozempic tablets), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 9Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.The lancet. Diabetes & endocrinology · 2025PMID 40961952Accessed 2 Oct 2026
Found an error? Report a correction.